OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

Mark E. Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine M. Tung, Anne Armstrong, Wenting Wu, Carsten Dietrich Goessl, Sarah Runswick, Pier Franco Conte

Memorial Sloan Kettering Cancer Center, New York, NY
Seoul National University Hospital, Seoul, Korea, Republic of (South)
Medical University of Gdańsk, Gdańsk, Poland
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Basser Center, University of Pennsylvania, Philadelphia, PA
National Hospital Organization Osaka National Hospital, Osaka, Japan
Institut Gustave Roussy, Villejuif, France
First Hospital of Jilin University, Changchun, China
Beth Israel Deaconess Medical Center and Dana-Farber Harvard Cancer Center, Boston, MA
The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
AstraZeneca, Gaithersburg, MD; AstraZeneca, Macclesfield, United Kingdom
University of Padova and Istituto Oncologico Veneto IRCCS, Padua, Italy